Shares of Express Scripts Holding Co (NASDAQ:ESRX) have been given an average rating of “Buy” by the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $95.56.
Separately, Zacks Investment Research cut Express Scripts from a “buy” rating to a “hold” rating in a research note on Wednesday, December 19th.
Institutional investors and hedge funds have recently modified their holdings of the business. Csenge Advisory Group acquired a new position in shares of Express Scripts during the third quarter worth about $30,000. Rehmann Capital Advisory Group increased its position in shares of Express Scripts by 29.7% during the third quarter. Rehmann Capital Advisory Group now owns 529 shares of the company’s stock worth $50,000 after acquiring an additional 121 shares during the last quarter. Palo Capital Inc. purchased a new stake in shares of Express Scripts during the third quarter worth about $124,000. Girard Partners LTD. purchased a new stake in shares of Express Scripts during the third quarter worth about $172,000. Finally, Fieldpoint Private Securities LLC increased its position in shares of Express Scripts by 40.1% during the third quarter. Fieldpoint Private Securities LLC now owns 2,095 shares of the company’s stock worth $199,000 after acquiring an additional 600 shares during the last quarter. Institutional investors own 84.87% of the company’s stock.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Further Reading: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.